A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine

International Immunology

Volumn 21, Issue 3, 2009, Pages 217-225

  Jamali, Abbas ^a   Mahdavi, Mehdi ^b   Hassan, Zuhair Muhammad ^b   Sabahi, Farzaneh ^b   Farsani, Mohammad Jazayeri ^b   Bamdad, Taravat ^b   Soleimanjahi, Hoorieh ^b   Motazakker, Morteza ^a   Shahabi, Shahram ^a  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Adjuvant; Cellular immunity; Endogenous opioids; Herpes simplex virus; Th1

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NALOXONE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DNA IMMUNIZATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NALOXONE; NARCOTIC ANTAGONISTS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 61349195331     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn139     Document Type: Article

References (60)

1. Schijns, V. E. 2003. Mechanisms of vaccine adjuvant activity: Initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21:829.
2. Greenland, J. R. and Letvin, N. L. 2007. Chemical adjuvants for plasmid DNA vaccines. Vaccine 25:3731.
3. Markel, H. 2005. The search for effective HIV vaccines. N. Engl. J. Med. 353:753.
4. Sharpe, S., Hanke, T., Tinsley-Bown, A. et al. 2003. Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology 313:13.
5. Forde, G. M. 2005. Rapid-response vaccines - does DNA offer a solution? Nat. Biotechnol. 23:1059.
6. Vogel, F. R. 1998. Adjuvants in perspective. In Brown, F. and Haaheim, L. R., eds, Modulation of the Immune Response to Vaccine Antigens, p. 241. Basel, Switzerland, Karger. Development in Biological Standardization.
7. Singh, M. and O'Hagan, D. T. 2003. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol. 33:469.
8. Rajput, Z. I., Hu, S. H., Xiao, C. W. and Arijo, A. G. 2007. Adjuvant effects of saponins on animal immune responses. J. Zhejiang. Univ. Sci. B 8:153.
9. Vogel, F. and Powell, M. 1995. A compendium of vaccine adjuvants and excipients. In Powell, M. and Neuman, M., eds, Vaccine Design, the Subunit and Adjuvant Approach, p. 141. Plenum Press, New York.
10. Gupta, R. K. and Siber, G. R. 1995. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13:1263.
11. McCarthy, L., Wetzel, M., Sliker, J. K., Eisenstein, T. K. and Rogers, T. J. 2001. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 62:111.
12. Sharp, B. M. 2006. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav. Immun. 20:9.
13. Molitor, T. W., Morilla, A., Risdahl, J. M., Murtaugh, M. P., Chao, C.C. and Peterson, P. K. 1992. Chronic morphine administration impairs cell-mediated immune responses in swine. J. Pharmacol. Exp. Ther. 260:581.
14. Carpenter, G. W. and Carr, D. J. 1995. Pretreatment with beta-funaltrexamine blocks morphine-mediated suppression of CTL activity in alloimmunized mice. Immunopharmacology 29:129.
15. Friedman, H., Newton, C. and Klein, T. W. 2003. Microbial infections, immunomodulation, and drugs of abuse. Clin. Microbiol. Rev. 16:209.
16. Sacerdote, P., Gaspani, L. and Panerai, A. E. 2000. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann. N. Y. Acad. Sci. 917:755.
17. Sacerdote, P., di San Secondo, V. E., Sirchia, G., Manfredi, B. and Panerai, A. E. 1998. Endogenous opioids modulate allograft rejection time in mice: Possible relation with Th1/Th2 cytokines. Clin. Exp. Immunol. 113:465.
18. Sacerdote, P., Manfredi, B., Gaspani, L. and Panerai, A. E. 2000. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 95:2031.
19. Romagnani, S. 2006. Regulation of the T cell response. Clin. Exp. Allergy 36:1357.
20. Claassen, E., de Leeuw, W., de Greeve, P., Hendriksen, C. and Boersma, W. 1992. Freund's complete adjuvant: An effective but disagreeable formula. Res. Immunol. 143:478. discussion 572.
21. Tagliabue, A. and Rappuoli, R. 2008. Vaccine adjuvants: The dream becomes real. Hum. Vaccin. 4:347.
22. Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E. and Bramwell, V. W. 2008. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364:272.
23. Lewcock, A. 2007. New Pandemic Flu Vaccine Gets EU Approval. In-Pharmatechnologist.com. http://www.in-pharmatechnologist.com/ Materials-Formulation/New-pandemic-flu-vaccine-gets-EU-approval. (3 September 2008, date last accessed).
24. Heinemann, L., Woodfield, L., Amer, M. and Hibma, M. 2008. Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59. Viral Immunol. 21:225.
25. Mbawuike, I. N., Acuna, C., Caballero, D. et al. 1996. Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell. Immunol. 173:64.
26. Hem, S. L. and White, J. L. 1995. Structure and properties of aluminum-containing adjuvants. Pharm. Biotechnol. 6:249.
27. www.accessdata.fda.gov. 2008. FDA Approved Drug Products. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm. (3 April 2008, date last accessed).
28. Burris, S., Norland, J. and Edlin, B. R. 2001. Legal aspects of providing naloxone to heroin users in the United States. Int. J. Drug Policy 12:237.
29. Jamali, A., Mahdavi, M., Shahabi, S. et al. 2007. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb. Pathog. 43:217.
30. Soleimanjahi, H., Roostaee, M. H., Rasaee, M. J. et al. 2006. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections. FEMS Immunol. Med. Microbiol. 46:100.
31. Osorio, Y. and Ghiasi, H. 2003. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes. J. Virol. 77:5774.
32. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55.
33. Nass, P. H., Elkins, K. L. and Weir, J. P. 2001. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine 19:1538.
34. Koelle, D. M. and Corey, L. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96.
35. Barcellini, W., Sacerdote, P., Borghi, M. O. et al. 1994. Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. Peptides 15:769.
36. Kojima, Y., Xin, K. Q., Ooki, T. et al. 2002. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 20:2857.
37. Pardoll, D. M. and Beckerleg, A. M. 1995. Exposing the immunology of naked DNA vaccines. Immunity 3:165.
38. Horner, A. A., Datta, S. K., Takabayashi, K. et al. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167:1584.
39. Poole, V. and Peterson, A. M. 2005. Pharmacotherapeutics for Advanced Practice: A Practical Approach, In. 2nd edn. p. 66. Lippincott Williams & Wilkins, Philadelphia, PA.
40. Philippe, D., Dubuquoy, L., Groux, H. et al. 2003. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J. Clin. Invest. 111:1329.
41. Khalil, Z. and Helme, R. D. 1990. Modulation of a peripheral inflammatory response to substance P by locally administered opioid receptor agonists. Neuropeptides 17:45.
42. Sternberg, E. M. 2006. Neural regulation of innate immunity: A coordinated nonspecific host response to pathogens. Nat. Rev. Immunol 6:318.
43. Chakass, D., Philippe, D., Erdual, E. et al. 2007. micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut 56:974.
44. Kirst, A., Wack, C., Lutz, W. K., Eggert, A., Kampgen, E. and Fischer, W. H. 2002. Expression of functional kappa-opioid receptors on murine dendritic cells. Immunol. Lett. 84:41.
45. Sacerdote, P. 2003. Effects of in vitro and in vivo opioids on the production of IL-12 and IL-10 by murine macrophages. Ann. N. Y. Acad. Sci. 992:129.
46. Mathers, A. R., Tckacheva, O. A., Janelsins, B. M., Shufesky, W. J., Morelli, A. E. and Larregina, A. T. 2007. In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1biased immune responses. J. Immunol. 178:7006.
47. Berman, A. S., Chancellor-Freeland, C., Zhu, G. and Black, P. H. 1996. Substance P primes murine peritoneal macrophages for an augmented proinflammatory cytokine response to lipopolysaccharide. Neuroimmunomodulation 3:141.
48. Bileviciute-Ljungar, I. and Spetea, M. 2001. Contralateral but not systemic administration of the kappa-opioid agonist U-50488H induces anti-nociception in acute hindpaw inflammation in rats. Br. J. Pharmacol. 132:252.
49. Kaneider, N. C., Kaser, A., Dunzendorfer, S., Tilg, H., Patsch, J. R. and Wiedermann, C. J. 2005. Neurokinin-1 receptor interacts with PrP(106-126)-induced dendritic cell migration and maturation. J. Neuroimmunol. 158:153.
50. Sin, J., Kim, J. J., Pachuk, C., Satishchandran, C. and Weiner, D. B. 2000. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol. 74:11173.
51. Lee, S., Gierynska, M., Eo, S. K., Kuklin, N. and Rouse, B. T. 2003. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect. 5:571.
52. Lovik, M., Alberg, T., Nygaard, U. C., Samuelsen, M., Groeng, E. C. and Gaarder, P. I. 2007. Popliteal lymph node (PLN) assay to study adjuvant effects on respiratory allergy. Methods 41:72.
53. Halford, W. P., Balliet, J. W. and Gebhardt, B. M. 2004. Reevaluating natural resistance to herpes simplex virus type 1. J. Virol. 78:10086.
54. Eisenstein, T. K., Rahim, R. T., Feng, P., Thingalaya, N. K. and Meissler, J. J. 2006. Effects of opioid tolerance and withdrawal on the immune system. J. Neuroimmune Pharmacol. 1:237.
55. Govitrapong, P., Suttitum, T., Kotchabhakdi, N. and Uneklabh, T. 1998. Alterations of immune functions in heroin addicts and heroin withdrawal subjects. J. Pharmacol. Exp. Ther. 286:883.
56. West, J. P., Dykstra, L. A. and Lysle, D. T. 1999. Immunomodulatory effects of morphine withdrawal in the rat are time dependent and reversible by clonidine. Psychopharmacology (Berl) 146:320.
57. Manfredi, B., Sacerdote, P., Bianchi, M., Locatelli, L., VeljicRadulovic, J. and Panerai, A. E. 1993. Evidence for an opioid inhibitory effect on T cell proliferation. J. Neuroimmunol. 44:43.
58. Reyes, L., Hartikka, J., Bozoukova, V. et al. 2001. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 19:3778.
59. Jimenez, G. S., Planchon, R., Wei, Q. et al. 2007. Vaxfectinformulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum. Vaccin. 3:157.
60. Lowrie, D. B. 2003. DNA vaccination, an update. In Robinson, A., Hudson, M. J. and Cranage, M. P., eds, Methods in Molecular Medicine, Vol. 87: Vaccine Protocols, 2nd edn. p. 377. Humana Press Inc, Totowa.